<DOC>
	<DOC>NCT00162240</DOC>
	<brief_summary>A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination with Metformin Therapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone</brief_summary>
	<brief_title>PPAR - Combination With Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 Diabetes HbA1c &gt; 7.0% and &lt; 10.0 % Mean serum triglyceride &lt; 600 mg/dL Body mass index &lt; 41 kg/m2 Fasting cpeptide &gt; 1.0 ng/mL History of myocardial infarction (MI) coronary angioplasty or bypass graft(s) valvular disease or repair unstable angina pectoris transient ischemic attack (TIA), cerebrovascular attack, or cerebrovascular accident (CVA) within 6 months Congestive heart failure NYHA Class III and IV Uncontrolled hypertension History of renal disease, peripheral vascular disease (PVD), pulmonary disease, gastrointestinal disease, active liver disease or endocrine disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Metabolics Diabetes New Onset</keyword>
</DOC>